Almost every transplant patient receives one of two different calcineurin inhibitors, either tacrolimus or CsA. to demonstrate equivalent CypB expression.(0.38 MB TIF) pone.0009815.s004.tif (372K) GUID:?7AC6AFAD-2FCA-4E2E-ABE0-87BD60A5B89D Figure S5: HCV NS5A binds CypA A) Coomassie staining of HIS-tagged E. coli purified proteins B) Western blot analysis using anti-HIS monoclonal antibody demonstrates NS5A in the GSTCypA complex but not in GST, and no CFP binds either GST or GSTCypA.(3.00 MB TIF) pone.0009815.s005.tif 16-Dehydroprogesterone (2.8M) GUID:?38FC6D6E-D164-4F3C-9D65-A234B9552795 Abstract Background Hepatitis C Virus (HCV) infection is a leading indication for liver transplantation. HCV infection reoccurs almost universally post transplant, decreasing both graft longevity and patient survival. The immunosuppressant, cyclosporine A (CsA) has potent anti-HCV activity ILK (phospho-Ser246) antibody towards both HCV replicons and the genotype 2a cell culture infectious virus. Previously, we isolated mutations in the 1bN replicon with less sensitivity to CsA that mapped to both NS5A and NS5B regions of the virus. Mutations in NS5A alone conferred decreased CsA susceptibility regardless of NS5B mutations. Methodology/Principal Findings We examined the mechanisms by which NS5A mutations contribute to CsA resistance and if they are strain dependent. Using in vitro mutagenesis, the amino acid position 321 mutation of NS5A was restored to the wild-type tyrosine residue conferring partial CsA susceptibility on the mutant replicon. The 321 mutation also alters CsA susceptibility of the JFH cell culture virus. Additionally, we demonstrated a novel CsA-sensitive interaction between NS5A and both cyclophilin A and B. Both the mutant NS5A and wild type NS5A bind cyclophilin in vitro. The NS5A: cyclophilin interaction requires both the NS5A region identified by the resistance mutants and cyclophilin catalytic 16-Dehydroprogesterone residues. In cell culture, NS5A from CsA resistant mutant has an enhanced interaction with cyclophilin B. Additionally; NS5B facilitates a stronger binding of mutant NS5A to endogenous cyclophilin B than wild-type in cell culture. Conclusions/Significance Collectively, this data suggests direct interactions between cyclophilins and NS5A are critical to understand for optimal use of cyclophilin inhibitors in anti-HCV therapy. Introduction HCV infects 200 million people worldwide. Current treatment options for HCV include pegylated interferon and ribavirin. However this treatment is not always effective or tolerated well . Thus, new therapies are urgently needed. Frequently, patients do not have symptoms from HCV infection until their liver is severely damaged. Liver transplantation becomes the only practical means of restoring health and requires long-term immunosuppression to prevent graft rejection. Almost every transplant patient receives one of two different calcineurin inhibitors, either tacrolimus or CsA. CsA and its nonimmunosuppressive analogs, DEBIO-25 and NIM811, show in vitro antiviral activity against the HCV 1a, 1b, and 2a experimental replicons that is related to their ability to inhibit a class of cellular Prolyl-peptidyl isomerases called cyclophilins (Cyp) , , . 16-Dehydroprogesterone Tacrolimus lacks this activity , . However, for transplant patients infected with HCV, it remains unclear if CsA or tacrolimus is the calcineurin inhibitor of choice. It was initially proposed that in vitro inhibition of HCV by CsA results from disruption of the interaction between the HCV polymerase, NS5B, and Cyclophilin B (CypB) . CypB enhances binding of NS5B to RNA , , . A previous study showed CsA addition to HeLa cell cultures results in relocalization and secretion of CypB . These findings were further corroborated by recent clinical data from HCV and HIV co-infected patients. The treatment of these co-infected patients with the CsA analog Debio-025 results in a decrease of CypB levels in peripheral blood mononuclear cells . This decrease in CypB levels coincides with a decrease in hepatitis C viral load. In contrast, Debio-025 treatment does not lead to decreases in Cyclophilin A (CypA) levels . While results are conflicting, siRNA data is most consistent with CypA rather than CypB playing.
Almost every transplant patient receives one of two different calcineurin inhibitors, either tacrolimus or CsA
- by eprf